These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 8136512)

  • 21. Comparison of L-758,298, a prodrug for the selective neurokinin-1 antagonist, L-754,030, with ondansetron for the prevention of cisplatin-induced emesis.
    Cocquyt V; Van Belle S; Reinhardt RR; Decramer ML; O'Brien M; Schellens JH; Borms M; Verbeke L; Van Aelst F; De Smet M; Carides AD; Eldridge K; Gertz BJ
    Eur J Cancer; 2001 May; 37(7):835-42. PubMed ID: 11313170
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety and efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of cisplatin-based highly emetogenic chemotherapy in patients with cancer: two randomised, active-controlled, double-blind, phase 3 trials.
    Rapoport BL; Chasen MR; Gridelli C; Urban L; Modiano MR; Schnadig ID; Poma A; Arora S; Kansra V; Schwartzberg LS; Navari RM
    Lancet Oncol; 2015 Sep; 16(9):1079-1089. PubMed ID: 26272769
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Recent improvements in antiemetic therapy].
    Roila F; Palladino MA; Ciccarese G; Basurto C
    Tumori; 1997; 83(2 Suppl):S3-14. PubMed ID: 9235727
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Oral ondansetron: an effective ambulatory complement to intravenous ondansetron in the control of chemotherapy-induced nausea and vomiting in children.
    Cohen IJ; Zehavi N; Buchwald I; Yaniv Y; Goshen Y; Kaplinsky C; Zaizov R
    Pediatr Hematol Oncol; 1995; 12(1):67-72. PubMed ID: 7703044
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Treatment of postoperative nausea and vomiting with ondansetron in patients administered anti-neoplastic agents].
    Morimoto Y; Nakamura M; Tamura T; Kunii T; Shimizu K; Miyauchi Y
    Masui; 1996 Sep; 45(9):1096-9. PubMed ID: 8905945
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Clinical efficacy of GG032X tablets, a new dosage form of ondansetron (fast dispersing tablet), on cisplatin-induced nausea and emesis].
    Ariyoshi Y; Nukariya N; Akasaka Y; Suminaga M; Ota J; Ikeda M; Taguchi T
    Gan To Kagaku Ryoho; 1997 Jun; 24(8):995-1011. PubMed ID: 9212810
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Effect of concurrent use of ondansetron hydrochloride and dexamethasone against nausea and vomiting in lung cancer patients receiving cisplatin].
    Tanimura S; Banba J; Tomoyasu H; Masaki M
    Gan To Kagaku Ryoho; 1998 Dec; 25(14):2275-81. PubMed ID: 9881085
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Efficacy of ondansetron in acute and delayed cisplatin-induced nausea and vomiting].
    Depierre A
    Bull Cancer; 1996 Feb; 83(2):147-53. PubMed ID: 8652909
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of ondansetron and ondansetron plus dexamethasone as antiemetic prophylaxis during cisplatin-containing chemotherapy.
    Smith DB; Newlands ES; Rustin GJ; Begent RH; Howells N; McQuade B; Bagshawe KD
    Lancet; 1991 Aug; 338(8765):487-90. PubMed ID: 1714532
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ondansetron: a pharmacoeconomic and quality-of-life evaluation of its antiemetic activity in patients receiving cancer chemotherapy.
    Plosker GL; Milne RJ
    Pharmacoeconomics; 1992 Oct; 2(4):285-304. PubMed ID: 10147044
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prevention of cisplatin-induced acute and delayed emesis by the selective neurokinin-1 antagonists, L-758,298 and MK-869.
    Van Belle S; Lichinitser MR; Navari RM; Garin AM; Decramer ML; Riviere A; Thant M; Brestan E; Bui B; Eldridge K; De Smet M; Michiels N; Reinhardt RR; Carides AD; Evans JK; Gertz BJ
    Cancer; 2002 Jun; 94(11):3032-41. PubMed ID: 12115394
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of ondansetron with metoclopramide in prevention of acute emesis associated with low dose & high dose cisplatin chemotherapy.
    Bhatia A; Tripathi KD; Sharma M
    Indian J Med Res; 2003 Jul; 118():33-41. PubMed ID: 14748464
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Combined use of ondansetron and other anti-emetics to control cisplatin-induced nausea and vomiting].
    Zeng WY
    Zhonghua Zhong Liu Za Zhi; 1993 Mar; 15(2):118-21. PubMed ID: 8223120
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Reduced maintenance of complete protection from emesis for women during chemotherapy cycles.
    Liaw CC; Chang HK; Liau CT; Huang JS; Lin YC; Chen JS
    Am J Clin Oncol; 2003 Feb; 26(1):12-5. PubMed ID: 12576917
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparative efficacy of three 5-HT3 antagonists (granisetron, ondansetron, and tropisetron) plus dexamethasone for the prevention of cisplatin-induced acute emesis: a randomized crossover study.
    Chua DT; Sham JS; Kwong DL; Kwok CC; Yue A; Foo YC; Chan R
    Am J Clin Oncol; 2000 Apr; 23(2):185-91. PubMed ID: 10776982
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ondansetron versus metoclopramide, both combined with dexamethasone, in the prevention of cisplatin-induced delayed emesis. The Italian Group for Antiemetic Research.
    J Clin Oncol; 1997 Jan; 15(1):124-30. PubMed ID: 8996133
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Anti-emetic effect and safety of ondansetron tablet in double-blind comparison with placebo].
    Ariyoshi Y; Ota K; Taguchi T; Furue H; Niitani H; Tsukagoshi S; Ikeda M; Akasaka Y; Ohta J; Suminaga M
    Gan To Kagaku Ryoho; 1992 Oct; 19(12):2057-70. PubMed ID: 1417014
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Drug treatment of chemotherapy-induced delayed emesis.
    Tavorath R; Hesketh PJ
    Drugs; 1996 Nov; 52(5):639-48. PubMed ID: 9118814
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ondansetron compared with granisetron in the prophylaxis of cisplatin-induced acute emesis: a multicentre double-blind, randomised, parallel-group study. The Ondansetron and Granisetron Emesis Study Group.
    Ruff P; Paska W; Goedhals L; Pouillart P; Rivière A; Vorobiof D; Bloch B; Jones A; Martin C; Brunet R
    Oncology; 1994; 51(1):113-8. PubMed ID: 8265095
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Study of rolapitant, a novel, long-acting, NK-1 receptor antagonist, for the prevention of chemotherapy-induced nausea and vomiting (CINV) due to highly emetogenic chemotherapy (HEC).
    Rapoport B; Chua D; Poma A; Arora S; Wang Y; Fein LE
    Support Care Cancer; 2015 Nov; 23(11):3281-8. PubMed ID: 25940030
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.